{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:45:58Z","timestamp":1787244358187,"version":"build-2736575974"},"reference-count":37,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,1,14]],"date-time":"2019-01-14T00:00:00Z","timestamp":1547424000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Pharmacokinetics"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.dmpk.2019.01.002","type":"journal-article","created":{"date-parts":[[2019,1,17]],"date-time":"2019-01-17T13:45:43Z","timestamp":1547732743000},"page":"172-180","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Rifamycin SV exhibits strong anti-inflammatory in\u00a0vitro activity through pregnane X receptor stimulation and NF\u03baB inhibition"],"prefix":"10.1016","volume":"34","author":[{"given":"Caridad","family":"Rosette","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances J.","family":"Agan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niccolette","family":"Rosette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Moro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Mazzetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesare","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara","family":"Gerloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.dmpk.2019.01.002_bib1","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000081990","article-title":"Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential","volume":"51","author":"Scarpignato","year":"2005","journal-title":"Chemotherapy"},{"key":"10.1016\/j.dmpk.2019.01.002_bib2","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ijantimicag.2013.04.020","article-title":"Anti-inflammatory and immunomodulatory activities of rifamycin SV","volume":"42","author":"Rosette","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.dmpk.2019.01.002_bib3","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1172\/JCI26283","article-title":"Mutual repression between steroid and xenobiotic receptor and NF-kappaB signaling pathways links xenobiotic metabolism and inflammation","volume":"116","author":"Zhou","year":"2006","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.dmpk.2019.01.002_bib4","doi-asserted-by":"crossref","first-page":"G1114","DOI":"10.1152\/ajpgi.00528.2006","article-title":"Pregnane X receptor activation ameliorates DSS-induced inflammatory bowel disease via inhibition of NF-kappaB target gene expression","volume":"292","author":"Shah","year":"2007","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.dmpk.2019.01.002_bib5","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/j.bcp.2010.08.022","article-title":"Pregnane-X-receptor mediates the anti-inflammatory activities of rifaximin on detoxification pathways in intestinal epithelial cells","volume":"80","author":"Mencarelli","year":"2010","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.dmpk.2019.01.002_bib6","doi-asserted-by":"crossref","first-page":"17882","DOI":"10.1074\/jbc.M601302200","article-title":"Role of NF-kappaB in regulation of PXR-mediated gene expression: a mechanism for the suppression of cytochrome P-450 3A4 by proinflammatory agents","volume":"281","author":"Gu","year":"2006","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.dmpk.2019.01.002_bib7","doi-asserted-by":"crossref","first-page":"456","DOI":"10.3389\/fphar.2016.00456","article-title":"Pregnane X receptor (PXR)-Mediated gene repression and cross-talk of PXR with other nuclear receptors via coactivator interactions","volume":"7","author":"Pavek","year":"2016","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.dmpk.2019.01.002_bib8","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1124\/jpet.107.121913","article-title":"Rifaximin is a gut-specific human pregnane X receptor activator","volume":"322","author":"Ma","year":"2007","journal-title":"J\u00a0Pharmacol Exp Therapeut"},{"issue":"Suppl 1","key":"10.1016\/j.dmpk.2019.01.002_bib9","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/apt.13436","article-title":"Review article: the potential mechanisms of action of rifaximin in the management of inflammatory bowel diseases","volume":"43","author":"Sartor","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dmpk.2019.01.002_bib10","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1124\/jpet.110.170225","article-title":"Therapeutic role of rifaximin in inflammatory bowel disease: clinical implication of human pregnane X receptor activation","volume":"335","author":"Cheng","year":"2010","journal-title":"J\u00a0Pharmacol Exp Therapeut"},{"key":"10.1016\/j.dmpk.2019.01.002_bib11","doi-asserted-by":"crossref","first-page":"e36075","DOI":"10.1371\/journal.pone.0036075","article-title":"Alleviation of gut inflammation by Cdx2\/Pxr pathway in a mouse model of chemical colitis","volume":"7","author":"Dou","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.dmpk.2019.01.002_bib12","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1124\/dmd.117.076927","article-title":"Involvement of NF-\u03baB, not PXR, in inflammation-mediated regulation of hepatic transporters","volume":"45","author":"Abualsunun","year":"2017","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2019.01.002_bib13","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1053\/j.gastro.2004.04.019","article-title":"Loss of detoxification in inflammatory bowel disease: dysregulation of pregnane X receptor target genes","volume":"127","author":"Langmann","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dmpk.2019.01.002_bib14","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1124\/dmd.115.068742","article-title":"Decreased pregnane X receptor expression in children with active crohn's disease","volume":"44","author":"Shakhnovich","year":"2016","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2019.01.002_bib15","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1097\/MIB.0000000000001062","article-title":"CYP3A4 activity is markedly lower in patients with crohn's disease","volume":"23","author":"Wilson","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.dmpk.2019.01.002_bib16","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1124\/mol.117.110155","article-title":"PXR: more than just a master xenobiotic receptor","volume":"93","author":"Oladimeji","year":"2018","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.dmpk.2019.01.002_bib17","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/mi.2017.31","article-title":"MDR1 deficiency impairs mitochondrial homeostasis and promotes intestinal inflammation","volume":"11","author":"Ho","year":"2018","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.dmpk.2019.01.002_bib18","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/ibd.20088","article-title":"Decreased P-glycoprotein (P-gp\/MDR1) expression in inflamed human intestinal epithelium is independent of PXR protein levels","volume":"13","author":"Blokzijl","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.dmpk.2019.01.002_bib19","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejps.2014.01.007","article-title":"Pregnane X receptor agonists enhance intestinal epithelial wound healing and repair of the intestinal barrier following the induction of experimental colitis","volume":"55","author":"Terc","year":"2014","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.dmpk.2019.01.002_bib20","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.immuni.2014.06.014","article-title":"Symbiotic bacterial metabolites regulate gastrointestinal barrier function via the xenobiotic sensor PXR and Toll-like receptor 4","volume":"41","author":"Venkatesh","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.dmpk.2019.01.002_bib21","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1124\/jpet.116.234096","article-title":"Pregnane X receptor activation attenuates inflammation-associated intestinal epithelial barrier dysfunction by inhibiting cytokine-induced myosin light-chain kinase expression and c-jun N-terminal kinase 1\/2 activation","volume":"359","author":"Garg","year":"2016","journal-title":"J\u00a0Pharmacol Exp Therapeut"},{"key":"10.1016\/j.dmpk.2019.01.002_bib22","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/00008571-200110000-00003","article-title":"The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants","volume":"11","author":"Zhang","year":"2001","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.dmpk.2019.01.002_bib23","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.cmet.2006.08.004","article-title":"Xenobiotic receptor meets NF-kappaB, a collision in the small bowel","volume":"4","author":"Xie","year":"2006","journal-title":"Cell Metab"},{"key":"10.1016\/j.dmpk.2019.01.002_bib24","doi-asserted-by":"crossref","first-page":"e0182071","DOI":"10.1371\/journal.pone.0182071","article-title":"NF-kappa B activation correlates with disease phenotype in Crohn's disease","volume":"12","author":"Han","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.dmpk.2019.01.002_bib25","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3109\/03602532.2012.737333","article-title":"Cell-based systems to assess nuclear receptor activation and their use in drug development","volume":"45","author":"Raucy","year":"2013","journal-title":"Drug Metab Rev"},{"key":"10.1016\/j.dmpk.2019.01.002_bib26","doi-asserted-by":"crossref","first-page":"E6","DOI":"10.1208\/aapsj070102","article-title":"A\u00a0simultaneous assessment of CYP3A4 metabolism and induction in the DPX-2 cell line","volume":"7","author":"Trubetskoy","year":"2005","journal-title":"AAPS J"},{"key":"10.1016\/j.dmpk.2019.01.002_bib27","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.tips.2013.11.005","article-title":"Regulation of transcription factor activity by interconnected post-translational modifications","volume":"35","author":"Filtz","year":"2014","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.dmpk.2019.01.002_bib28","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.2174\/1389200214666131211153307","article-title":"Post-translational and post-transcriptional modifications of pregnane X receptor (PXR) in regulation of the cytochrome P450 superfamily","volume":"14","author":"Smutny","year":"2013","journal-title":"Curr Drug Metabol"},{"key":"10.1016\/j.dmpk.2019.01.002_bib29","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.taap.2003.12.027","article-title":"PXR (NR1I2): splice variants in human tissues, including brain, and identification of neurosteroids and nicotine as PXR activators","volume":"199","author":"Lamba","year":"2004","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.dmpk.2019.01.002_bib30","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ejphar.2011.06.058","article-title":"Inhibition of NF-kappaB by a PXR-dependent pathway mediates counter-regulatory activities of rifaximin on innate immunity in intestinal epithelial cells","volume":"668","author":"Mencarelli","year":"2011","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.dmpk.2019.01.002_bib31","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3389\/fphar.2016.00120","article-title":"Rifaximin improves Clostridium difficile toxin A-induced toxicity in caco-2 cells by the PXR-dependent TLR4\/MyD88\/NF-kappaB pathway","volume":"7","author":"Esposito","year":"2016","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.dmpk.2019.01.002_bib32","doi-asserted-by":"crossref","first-page":"G716","DOI":"10.1152\/ajpgi.00472.2010","article-title":"Immune and nonimmune components orchestrate the pathogenesis of inflammatory bowel disease","volume":"300","author":"Danese","year":"2011","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.dmpk.2019.01.002_bib33","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1172\/JCI41514","article-title":"Pregnane X receptor activation induces FGF19-dependent tumor aggressiveness in humans and mice","volume":"121","author":"Wang","year":"2011","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.dmpk.2019.01.002_bib34","doi-asserted-by":"crossref","first-page":"8390595","DOI":"10.1155\/2017\/8390595","article-title":"The intricate link among gut \"immunological niche,\" microbiota, and xenobiotics in intestinal pathology","volume":"2017","author":"Pagliari","year":"2017","journal-title":"Mediat Inflamm"},{"key":"10.1016\/j.dmpk.2019.01.002_bib35","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1111\/nmo.12358","article-title":"Cytokine imbalance in irritable bowel syndrome: a systematic review and meta-analysis","volume":"26","author":"Bashashati","year":"2014","journal-title":"Neuro Gastroenterol Motil"},{"key":"10.1016\/j.dmpk.2019.01.002_bib36","doi-asserted-by":"crossref","first-page":"e258","DOI":"10.1111\/j.1463-1318.2012.02926.x","article-title":"Mucosal tumour necrosis factor alpha in diverticular disease of the colon is overexpressed with disease severity","volume":"14","author":"Tursi","year":"2012","journal-title":"Colorectal Dis"},{"key":"10.1016\/j.dmpk.2019.01.002_bib37","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1111\/nmo.12670","article-title":"Increased serum levels of lipopolysaccharide and antiflagellin antibodies in patients with diarrhea-predominant irritable bowel syndrome","volume":"27","author":"Dlugosz","year":"2015","journal-title":"Neuro Gastroenterol Motil"}],"container-title":["Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436718301538?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436718301538?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T19:54:19Z","timestamp":1761162859000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347436718301538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S1347436718301538"],"URL":"https:\/\/doi.org\/10.1016\/j.dmpk.2019.01.002","relation":{},"ISSN":["1347-4367"],"issn-type":[{"value":"1347-4367","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rifamycin SV exhibits strong anti-inflammatory in\u00a0vitro activity through pregnane X receptor stimulation and NF\u03baB inhibition","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Pharmacokinetics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmpk.2019.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}